Cure8 research brief
Cure8 research brief
Basal crypt dysplasia is easy to miss but linked to higher risk of advanced colorectal neoplasia in longstanding IBD. Improved recognition and use of p53 immunohistochemistry or complementary biomarkers could affect surveillance and diagnostic decisions.
Gastroenterologists; GI pathologists; clinicians managing IBD surveillance; researchers in IBD-associated cancer and biomarkers.
This is a pathology-focused review for clinicians and researchers.
It summarizes the histopathological definition and clinicopathological significance of BCD, the biological rationale for p53 alterations in colitis-associated carcinogenesis, and practical guidance on interpreting p53 immunostaining patterns (overexpression or complete absence) confined to basal crypts as supportive evidence for dysplasia.
The review also discusses limitations of p53 IHC, reproducibility issues in diagnosing BCD, and notes other biomarkers under study (SATB2) that may complement p53 in difficult cases.
This is a review article synthesizing existing studies and expert guidance. Full text access may require institutional subscription. p53 immunohistochemistry is an ancillary diagnostic tool with known limitations; the article also reviews reproducibility issues and emerging complementary biomarkers.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.